Upcoming Events
  1. ALTG open MAC and SAC meetings

    November 20
  2. Virtual 2020 World Conference on Lung Cancer Singapore

    January 28, 2021 @ 8:00 am - January 31, 2021 @ 5:00 pm

Thoracic oncology highlights from ASCO2020 webinar- recording and evaluation survey

Please fill in the evaluation survey if you have not already done so by clicking on the survey icon at the base of your webinar console.

Please access the recording and evaluation survey here

ALTG awarded $12 million in funding

The ALTG is pleased to announce over $12 million in funding has been successfully awarded to ALTG, NHMRC Clinical Trial Centre and the Australian Genomic Cancer Medicine Centre for the ASPiRATION project. In this ground-breaking precision medicine study, led by ALTG President A/Prof Nick Pavlakis and ALTG Scientific Advisory Committee Chair, Prof Ben Solomon, ASPiRATION will explore the benefit of routine comprehensive genomic profiling in 1000 newly-diagnosed metastatic, non-squamous, NSCLC patients in Australia. The enhanced genomic profiling will assist in personalising patient care by matching patients to targeted treatments as early as possible to improve patient outcomes.

Lung Foundation Australia News – Supporting Medicare Subsidies for Pulmonary Rehabilitation

Lung Foundation Australia has applied to the Medical Services Advisory Committee (MSAC) for pulmonary rehabilitation (PR) programs and follow-up pulmonary maintenance exercise (PME) programs for patients with COPD and other chronic lung diseases to be subsidised on the Medicare Benefits Schedule (MBS).

The Lung Foundation lodged its application with MSAC in December 2014. The draft protocol is currently under review by the Protocol Advisory Sub-committee (PASC) and is expected to be open for public comment from 5 October 2015 for a period of six weeks.

Current situation:

  • There is no national funding mechanism for pulmonary rehabilitation in the community, despite evidence that it can be provided safely in a community setting with appropriately skilled physiotherapists and/or exercise physiologists.
  • Access to pulmonary rehabilitation is limited – approximately 260 programs are available throughout Australia to service a potential patient population of approximately 750,000.
  • Pulmonary rehabilitation is conducted mainly in the hospital and health service setting and is limited mostly to urban and larger regional settings.

Benefits:

  • Together with smoking cessation pulmonary rehabilitation is one of the most evidence-based interventions with NH&MRC Level I&II evidence to support its benefits [COPD-X Guidelines]. The number needed to treat (NNT) to avoid one hospital admission (for post exacerbation/flare up of symptoms) is 4
  • Pulmonary rehabilitation is effective in improving patients’ quality of life and reducing health care costs, mainly through reduced hospital admissions and length of hospital stay.
  • Due to the known benefits for preventing hospital readmissions, pulmonary rehabilitation is recommended (and in some states, mandated) following discharge of patients who have been hospitalised with an acute exacerbation of COPD.

When the time comes for public comment on the protocol, if you would like to support this application you may do so by submitting a feedback form to the PASC committee.  Our application number is 1405. Any support would be most appreciated.